Zevra Therapeutics Inc (ZVRA) Stock Price, Quote & News

Company Profile

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug pro...

Industry: Biotechnology

Sector: Healthcare

Phone: 321 939 3416

Website: zevra.com

Address:

1180 Celebration Boulevard, Suite 103, Celebration, United States

DevAd Dec. 13 at 10:39 PM

$ZVRA below 8 I'm buying!

0 · Reply

KemPharm_rocks Dec. 13 at 2:56 PM

$ZVRA “…and the waiting…is the hardest part.” - Tom Petty 🤣

1 · Reply

DataJim Dec. 13 at 12:34 PM

$ZVRA I sold $15 Jan 2027 calls on most of my shares. So as this swings my portfolio value doesn’t see much impact since the calls track in the opposite direction.

1 · Reply

DataJim Dec. 13 at 8:33 AM

$TLSA There seems to be a lack of trust. The fact that insiders own 40% should help, anything they do to you they’re doing to themselves. At $ZVRA your average retail shareholder owns more than half the board members. At $NGENF they raised money by selling to themselves on the cheap along with warrants. The last time I was invested in a company, I didn’t trust it was $SAVA and I definitely learned to my lesson there.

2 · Reply

Bayrider Dec. 12 at 9:55 PM

$ZVRA 53,000 options granted to 3 new employees as inducement awards.

5 · Reply

Capdoc Dec. 12 at 9:03 PM

$ZVRA revenue per share $1.55 x 15=$23.25 plus $3.59 per share cash. The ceo wanted to sell for 14-15 per share. Got to be worth more than 8.35 per share. Never mind pipes and astarys.

0 · Reply

guffy Dec. 12 at 8:24 PM

$ZVRA At what based these analysts providing target $23 to $29?…All scam. Isn’t?

1 · Reply

lance1965 Dec. 12 at 5:54 PM

$ZVRA

0 · Reply

PencilNeckGeek Dec. 12 at 5:44 PM

$ZVRA $9.50 by 2027?

1 · Reply

MoneyGroupLLC Dec. 12 at 5:05 PM

Enter: $ZVRA Calls Strike Price: $9 Expiry Date: JAN 16 2026 Buy in Price: $0.65 - $0.70 Sell Price: $1.12 Profit : +73% (Turn every $1 into $1.73) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Dec 2, 2025, 7:30 AM EST - 11 days ago

Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD

Nov 20, 2025, 4:05 PM EST - 23 days ago

Zevra Therapeutics, Inc. Announces CFO Transition

Nov 5, 2025, 9:01 PM EST - 5 weeks ago

Zevra Therapeutics, Inc. (ZVRA) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 4:05 PM EST - 5 weeks ago

Zevra Reports Third Quarter 2025 Financial Results and Corporate Update

Oct 29, 2025, 7:30 AM EDT - 6 weeks ago

Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference

Oct 27, 2025, 7:30 AM EDT - 6 weeks ago

Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call

Sep 18, 2025, 7:30 AM EDT - 3 months ago

Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyrate)

Sep 4, 2025, 7:30 AM EDT - 3 months ago

Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)

Aug 28, 2025, 7:30 AM EDT - 3 months ago

Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)

Aug 26, 2025, 7:30 AM EDT - 3 months ago

Zevra Therapeutics to Participate at Upcoming Investor Conferences in September

Aug 12, 2025, 8:43 PM EDT - 4 months ago

Zevra Therapeutics, Inc. (ZVRA) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:05 PM EDT - 4 months ago

Zevra Reports Second Quarter 2025 Financial Results and Corporate Update

Aug 4, 2025, 7:30 AM EDT - 4 months ago

Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call

Jul 28, 2025, 6:00 AM EDT - 4 months ago

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

Jul 18, 2025, 7:30 AM EDT - 5 months ago

Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)

Jul 16, 2025, 7:30 AM EDT - 5 months ago

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism

May 29, 2025, 4:35 PM EDT - 7 months ago

Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

May 21, 2025, 7:30 AM EDT - 7 months ago

All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees

May 13, 2025, 10:45 PM EDT - 7 months ago

Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript

May 6, 2025, 7:30 AM EDT - 7 months ago

Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call

Apr 17, 2025, 7:30 AM EDT - 8 months ago

Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism

Apr 7, 2025, 7:30 AM EDT - 8 months ago

Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Mar 31, 2025, 4:12 PM EDT - 9 months ago

Zevra Therapeutics Files Preliminary Proxy

Mar 11, 2025, 8:16 PM EDT - 9 months ago

Zevra Therapeutics, Inc. (ZVRA) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 4:05 PM EDT - 9 months ago

Zevra Reports Full Year 2024 and Fourth Quarter Financial Results

Feb 28, 2025, 7:30 AM EST - 10 months ago

Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,' to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C

Feb 27, 2025, 7:30 AM EST - 10 months ago

Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

Feb 26, 2025, 9:46 AM EST - 10 months ago

Zevra to Report 2024 Fourth Quarter and Full Year Financial Results

Feb 24, 2025, 4:02 PM EST - 10 months ago

Zevra to Participate at Upcoming Investor Conferences

Jan 30, 2025, 7:30 AM EST - 11 months ago

Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™

Jan 29, 2025, 4:05 PM EST - 11 months ago

Zevra Therapeutics to Participate at Upcoming Investor Conferences

Jan 8, 2025, 11:13 AM EST - 1 year ago

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

AMGN BBIO BMY IOVA LLY MDGL MRK

Dec 17, 2024, 7:30 AM EST - 1 year ago

Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024

Dec 6, 2024, 5:00 PM EST - 1 year ago

Zevra Therapeutics Announces Organizational Changes

Nov 21, 2024, 4:51 PM EST - 1 year ago

Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C

Nov 13, 2024, 7:12 AM EST - 1 year ago

Zevra Therapeutics, Inc. (ZVRA) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 4:36 PM EST - 1 year ago

Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting

Nov 6, 2024, 7:30 AM EST - 1 year ago

Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024

Oct 10, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

Sep 24, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024

Sep 20, 2024, 12:08 PM EDT - 1 year ago

Zevra Therapeutics' MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C

Sep 20, 2024, 10:14 AM EDT - 1 year ago

US FDA approves Zevra's genetic disorder treatment

Sep 6, 2024, 8:30 AM EDT - 1 year ago

Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

Aug 13, 2024, 9:45 PM EDT - 1 year ago

Zevra Therapeutics, Inc. (ZVRA) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 12:00 AM EDT - 1 year ago

Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Zevra Therapeutics Announces Proposed Public Offering of Common Stock

Aug 7, 2024, 9:34 AM EDT - 1 year ago

Zevra Therapeutics to Present at Canaccord Genuity's 44th Annual Growth Conference

Aug 2, 2024, 5:50 PM EDT - 1 year ago

FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C

DevAd Dec. 13 at 10:39 PM

$ZVRA below 8 I'm buying!

0 · Reply

KemPharm_rocks Dec. 13 at 2:56 PM

$ZVRA “…and the waiting…is the hardest part.” - Tom Petty 🤣

1 · Reply

DataJim Dec. 13 at 12:34 PM

$ZVRA I sold $15 Jan 2027 calls on most of my shares. So as this swings my portfolio value doesn’t see much impact since the calls track in the opposite direction.

1 · Reply

DataJim Dec. 13 at 8:33 AM

2 · Reply

Bayrider Dec. 12 at 9:55 PM

$ZVRA 53,000 options granted to 3 new employees as inducement awards.

5 · Reply

Capdoc Dec. 12 at 9:03 PM

$ZVRA revenue per share $1.55 x 15=$23.25 plus $3.59 per share cash. The ceo wanted to sell for 14-15 per share. Got to be worth more than 8.35 per share. Never mind pipes and astarys.

0 · Reply

guffy Dec. 12 at 8:24 PM

$ZVRA At what based these analysts providing target $23 to $29?…All scam. Isn’t?

1 · Reply

lance1965 Dec. 12 at 5:54 PM

$ZVRA

0 · Reply

PencilNeckGeek Dec. 12 at 5:44 PM

$ZVRA $9.50 by 2027?

1 · Reply

MoneyGroupLLC Dec. 12 at 5:05 PM

0 · Reply

ReggieWhit2 Dec. 12 at 4:29 PM

$ZVRA I wonder when the board or whoever will get together to determine year end bonus opportunities for Neil and others. You ever wonder what the criterion and goals are for Neil? He'll receive his bonus shares at our expense, and the results of his year long accomplishments will be shrouded in secrecy. The one thing we can see for sure is the shareholder value he has created and the openness in his management style. He deserves every penny and freebie!

2 · Reply

DevAd Dec. 12 at 4:11 PM

$ZVRA

0 · Reply

BMW2002 Dec. 12 at 4:10 PM

$ZVRA

0 · Reply

trading_momentum_x Dec. 12 at 11:18 AM

$ZVRA - a break down and rejected from the 20 DMA at 8.75. Next target down is the lower Bollingers at 8.

0 · Reply

jemer Dec. 12 at 2:04 AM

$ZVRA

1 · Reply

BigGainTom Dec. 12 at 1:43 AM

$ZVRA did rod selll

0 · Reply

MikeyNJ Dec. 11 at 10:35 PM

$ZVRA Haven't posted much here lately as there is really nothing to say. I am going to hold this until it plays out one way or another. I also admit that I have no clue as to what is going on and therefore holding this in blind faith. On paper, it looks dirt cheap but that has been the case forever. We see institutional ownership increasing yet it has no influence on the stock price. Retail is getting tired of the long wait. I think complacency has set it as time has passed. Most of the hardcore longs post here infrequently. If the stock price showed any signs of life reflecting the potential we believe exists, that would instill some confidence. Yet, the stock's behavior makes one question if the bull thesis is intact. Management remains quiet with little communication. There is also no significant insider buying. I get the frustration here as this has been dead money for way too long. I still believe this is cheap and sooner or later will work. But, this one is not easy!

2 · Reply

Jhh3796 Dec. 11 at 8:43 PM

$ZVRA You know what I want for Christmas? A new CEO for ZVRA.

1 · Reply

PencilNeckGeek Dec. 11 at 6:49 PM

$ZVRA What do you rate this stock from 1-10 on the shit show scale?

3 · Reply

SETesla77 Dec. 11 at 5:52 PM

$ZVRA at this point I guess back to $7 is ok so I can continue to buy more shares?!? 🤷‍♂️

0 · Reply

jemer Dec. 11 at 3:14 PM

$ZVRA Tudor Investment Corp just bought 447,000 shares and 40,800 call shares. What do they know?

4 · Reply

HuntingHighAndLow Dec. 11 at 2:44 PM

$ZVRA Zevra trying to hire all those medical liaisons to try to turn the tide? Searching for Miplyffa in Texas, December 2025: “Generally, if a drug is not listed on the drug list it is not covered.” https://www.myprime.com/content/dam/prime/memberportal/WebDocs/2025/Formularies/HIM/2025_TX_4T_HIM.pdf

1 · Reply

Market Cap	468.96M
Revenue (ttm)	23.61M
Net Income (ttm)	-105.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-446.89%
Debt to Equity Ratio	0.46

Volume	624,200
Avg Vol	1,574,196
Day's Range	N/A - N/A
Shares Out	56.30M
Stochastic %K	23%
Beta	1.01
Analysts	Strong Sell
Price Target	$22.86